DILIC
NKTR icon

Dai-ichi Life Insurance Company’s Nektar Therapeutics NKTR Stock Holding History

Dai-ichi Life Insurance Company’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-809
Closed -$432K – 530
2019
Q2 		$432K Hold
809
– – 0.01% 476
2019
Q1 		$408K Hold
809
– – 0.01% 465
2018
Q4 		$399K Buy
809
+6
+0.7% +$3.62K 0.01% 437
2018
Q3 		$734K Hold
803
– – 0.02% 426
2018
Q2 		$588K Buy
+803
New +$926K 0.01% 435

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dai-ichi Life Insurance Company's NKTR Position: Q3 2019 in Review

Dai-ichi Life Insurance Company sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 809 shares — an estimated $432K sold.

Dai-ichi Life Insurance Company first reported a position in NKTR in Q2 2018 and held it in 5 quarters. The position peaked at $734K in Q3 2018. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • Dai-ichi Life Insurance Company reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Dai-ichi Life Insurance Company sold 809 Nektar Therapeutics shares in Q3 2019, an estimated $432K.
  • Dai-ichi Life Insurance Company first reported a position in Nektar Therapeutics in Q2 2018 and held it in 5 quarters.
  • Dai-ichi Life Insurance Company's Nektar Therapeutics position peaked at $734K in Q3 2018.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Dai-ichi Life Insurance Company's 13F filing for Q3 2019, filed 13 Nov 2019.